• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Philips’ HealthSuite will track Ypsomed’s connected self-medication devices

October 5, 2018 By Nancy Crotti

 

Philips’ HealthSuite platform will soon connect with Ypsomed’s self-medication devices.

Philips and Ypsomed said today that they will jointly develop a solution for Ypsomed’s new self-medication adherence monitoring services based on Philips’ HealthSuite digital platform.

The combination of Ypsomed’s connected devices and Philips’ (NYSE:PHG) cloud-based digital platform will allow Ypsomed’s pharmaceutical customers to deliver value-added services aimed at improving patient outcomes, the companies said in a joint statement. They intend to sign the definitive agreements in the fourth quarter of 2018.

Ypsomed describes its SmartServices as a new turnkey digital solution for medication adherence monitoring and smart device management. Philips’ HealthSuite digital platform provides tools and services focused on ease-of-integration, digital lifecycle management, and end-to-end security, according to that company.

Ypsomed makes injections pens, autoinjectors and infusion systems to administer liquid drugs. The new digital services aim to address a wide range of device-oriented challenges and support self-medication services for patients across chronic disease states, such as diabetes, multiple sclerosis, and rheumatoid arthritis.

“Our partnership with Philips aims at embedding smart devices in a digital health ecosystem that simplifies access to therapy-relevant medication adherence data,” said Ulrike Bauer, senior vice president of Ypsomed Delivery Systems, in the statement. “This will allow our pharmaceutical customers to focus on building therapy-specific digital solutions for patients, caregivers, and physicians.”

Integrating Ypsomed’s smart devices and data into HealthSuite will enable pharma companies to achieve shorter time-to-market, scale-up solutions in a secure HIPAA-compliant way, and integrate data from Ypsomed devices with other data sources to support other value-added use cases, said Philips’ HealthSuite business leaderDale Wiggins.

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Research & Development, Technology, Uncategorized Tagged With: Philips, Ypsomed

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS